Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Longitudinal study of 56 households with at least one member who had COVID-19 to compare the course of illness, immune responses, and long-term consequences of SARS-CoV-2 infection in HED patients with those of control subjects of the same age group. Complete households are investigated, including women who are pregnant when exposed to the virus and their newborn child(ren).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Hypohidrotic Ectodermal Dysplasia | all household members with hypohidrotic ectodermal dysplasia (HED), a rare hereditary developmental disorder | ||
| Control | individuals of the same age group, but without HED, including pregnant women |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| age-dependence of SARS-CoV-2 infection | registry of household members with and without symptoms of COVID-19 (entire households) | 3 months from the point in time at which the first household member shows symptoms of COVID-19 |
| percentage of household members infected by SARS-CoV-2 | The infection rate is determined on the basis of specific PCR tests and detectibility of antibodies against SARS-CoV-2. | 3 months from the point in time at which the first household member shows symptoms of COVID-19 |
| duration of primary COVID-19 symptoms | The possible association between the length of time with symptoms of COVID-19 and specific immune responses, in particular the development of virus-neutralizing antibodies, is studied. | 2 months from the onset of COVID-19 symptoms |
| frequency of late-onset cardiovascular complications | Patient-reported known and yet unknown long-term consequences of COVID-19 are registered and investigated further (questionnaire, specific data confirmed by clinical examination). | 2-12 months from the onset of COVID-19 symptoms |
| frequency of postviral fatigue | Patient-reported symptoms of fatigue are registered (questionnaire). | 2-12 months from the onset of COVID-19 symptoms |
| frequency of noticeable temporary hair loss after COVID-19 | Patient-reported extent of hair loss is registered (questionnaire). | 2-12 months from the onset of COVID-19 symptoms |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
households with children and/or adolescents and at least one member who has or had a SARS-CoV-2 infection
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Holm Schneider, MD | University Hospital Erlangen | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Erlangen | Erlangen | Germany |
Not provided
| ID | Term |
|---|---|
| D053358 | Ectodermal Dysplasia 1, Anhidrotic |
| ID | Term |
|---|---|
| D004476 | Ectodermal Dysplasia |
| D000015 | Abnormalities, Multiple |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Not provided
Not provided
Not provided
Not provided
Not provided
serum, peripheral blood mononuclear cells
| D012868 | Skin Abnormalities |
| D040181 | Genetic Diseases, X-Linked |
| D030342 | Genetic Diseases, Inborn |
| D012873 | Skin Diseases, Genetic |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |